Ohio study aims to beat lung cancer with smarter testing

NCT ID NCT03199651

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This large study in Ohio is looking at whether advanced genomic testing and immunotherapy decision support can help people with stage IV non-small cell lung cancer live longer and have a better quality of life. Researchers will compare standard care with a more personalized approach that uses tumor and blood samples to guide treatment. The study also includes support for smoking cessation and tracks costs to see if the approach is worth it.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this study could show that personalized treatment decisions based on genomic testing improve survival and quality of life for people with advanced lung cancer.
What could go wrong
This is an observational and randomized study, not a test of a new drug. Results depend on many factors, and improvements may be modest or not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CIGARETTE SMOKER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Ohio State University Comprehensive Cancer Center

    RECRUITING

    Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.